UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of resveratrol may prevent cancer. PURPOSE: This phase I trial is studying the side effects and best dose of resveratrol in preventing cancer in healthy participants.

Detailed Description
-----------------
OBJECTIVES: Determine the concentration of resveratrol and its metabolites in the plasma, urine, and feces of healthy participants. Correlate dose with systemic concentration of this drug and its metabolites in these participants. Determine the safety of this drug in these participants. OUTLINE: This is an open-label, dose-escalation, multicenter study. Beginning 5 days before study drug administration, participants are put on a controlled diet (avoiding all resveratrol-containing food or drink) for washout. Participants receive oral resveratrol once on day 1. Cohorts of 10 participants receive escalating doses of resveratrol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 10 participants experience dose-limiting toxicity. A total of 16 participants are treated at the MTD. Participants are followed at 2 and 7 days. PROJECTED ACCRUAL: A total of 10-40 participants will be accrued for this study within 6 months.

Official Title
-----------------
Phase I Single-Dose Safety and Phamacokinetics Clinical Study of Resveratrol AKA IRB 2003-424

Conditions
-----------------
Unspecified Adult Solid Tumor, Protocol Specific

Intervention / Treatment
-----------------
* Drug: resveratrol


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Healthy participants PATIENT CHARACTERISTICS: Age 18 to 80 Performance status WHO 0-1 Life expectancy Not specified Hematopoietic Absolute neutrophil count > 1,500/mm^3 Platelet count 120,000-450,000mm^3 Hemoglobin 10.5-17.5 g/dL for women OR 11.5-19.0 g/dL for men Hepatic Bilirubin 0.05-1.2 mg/dL AST and ALT < 1.5 times normal Renal Creatinine normal Urinalysis normal Other Not pregnant or nursing Negative pregnancy test Fertile participants must use effective contraception Willing to abstain from ingesting large quantities of resveratrol-containing foods Willing to spend 24 hours in the hospital No cancer diagnosis that is currently under treatment, is clinically detectable, or that has been treated within the past 5 years except basal cell or squamous cell skin cancer No concurrent excessive alcohol intake (>21 units per week for men; 14 units per week for women) PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Concurrent hormone replace ment therapy allowed Concurrent oral or depot contraceptives allowed Radiotherapy Not specified Surgery Not specified Other At least 2 weeks since prior and no concurrent vitamin supplements of any type More than 6 months since prior and no concurrent participation in any other experimental study No other concurrent chronic medications, including over-the-counter medications, herbal/natural preparations, or dietary supplements No other concurrent prescribed medication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: resveratrol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
unspecified adult solid tumor, protocol specific